Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study

Published:2014-10 Issue: Volume:27 Page:49-53
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Li Jun-Feng,Liu Shuang,Ren Feng,Liu Mei,Wu Hui-Li,Chen Yu,Zou Huai-Bin,Bai Li,Li Ying,Zheng Su-Jun,Duan Zhong-Ping

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference27 articles.

1. Epidemiology and natural history of HCV infection;Hajarizadeh;Nat Rev Gastroenterol Hepatol,2013

2. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors;Missiha;Gastroenterology,2008

3. Clinical outcome of hepatitis C as a function of mode of transmission;Gordon;Hepatology,1998

4. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis;Di Bisceglie;Hepatology,1991

5. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade;Koretz;Ann Intern Med,1993

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of HCV Antibody and its Associated Factors: A Study from Sentinel Hospitals in China;BIOMED ENVIRON SCI;2023

2. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China;Frontiers in Pharmacology;2021-10-15

3. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C;Applied Health Economics and Health Policy;2020-11-19

4. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective;BMJ Global Health;2020-11

5. Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis;Frontiers in Oncology;2020-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3